Search for: "Eli Lilly "
Results 581 - 600
of 2,136
Sort by Relevance
|
Sort by Date
14 Mar 2016, 3:23 am
. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences. [read post]
11 Mar 2016, 1:25 pm
Normal pharma contract: Eli Lilly v. [read post]
11 Mar 2016, 6:02 am
, Day 24: Missing Balance on IP Border Measures, Day 25: The Treaties With the Treaty, Day 26: Why It Limits Canadian Cultural Policies, Day 27: Source Code Disclosure Confusion, Day 28: Privacy Risks from Source Code Rules, Day 29: Cultural Policy Innovation Uncertainty, Day 30: Losing Our Way on Geographical Indications, Day 31: Canadian Trademark Law Overhaul, Day 32: Illusory Safeguards Against Encryption Backdoors, Day 33: Setting the Rules for a Future Pharmacare Program, Day 34: PMO Was… [read post]
10 Mar 2016, 6:20 am
, Day 24: Missing Balance on IP Border Measures, Day 25: The Treaties With the Treaty, Day 26: Why It Limits Canadian Cultural Policies, Day 27: Source Code Disclosure Confusion, Day 28: Privacy Risks from Source Code Rules, Day 29: Cultural Policy Innovation Uncertainty, Day 30: Losing Our Way on Geographical Indications, Day 31: Canadian Trademark Law Overhaul, Day 32: Illusory Safeguards Against Encryption Backdoors, Day 33: Setting the Rules for a Future Pharmacare Program, Day 34: PMO Was… [read post]
9 Mar 2016, 11:43 am
Cir.2010) (quoting Eli Lilly & Co. v. [read post]
9 Mar 2016, 6:06 am
, Day 24: Missing Balance on IP Border Measures, Day 25: The Treaties With the Treaty, Day 26: Why It Limits Canadian Cultural Policies, Day 27: Source Code Disclosure Confusion, Day 28: Privacy Risks from Source Code Rules, Day 29: Cultural Policy Innovation Uncertainty, Day 30: Losing Our Way on Geographical Indications, Day 31: Canadian Trademark Law Overhaul, Day 32: Illusory Safeguards Against Encryption Backdoors, Day 33: Setting the Rules for a Future Pharmacare Program, Day 34: PMO Was… [read post]
8 Mar 2016, 6:02 am
, Day 24: Missing Balance on IP Border Measures, Day 25: The Treaties With the Treaty, Day 26: Why It Limits Canadian Cultural Policies, Day 27: Source Code Disclosure Confusion, Day 28: Privacy Risks from Source Code Rules, Day 29: Cultural Policy Innovation Uncertainty, Day 30: Losing Our Way on Geographical Indications, Day 31: Canadian Trademark Law Overhaul, Day 32: Illusory Safeguards Against Encryption Backdoors, Day 33: Setting the Rules for a Future Pharmacare Program, Day 34: PMO Was… [read post]
7 Mar 2016, 7:50 am
, Day 24: Missing Balance on IP Border Measures, Day 25: The Treaties With the Treaty, Day 26: Why It Limits Canadian Cultural Policies, Day 27: Source Code Disclosure Confusion, Day 28: Privacy Risks from Source Code Rules, Day 29: Cultural Policy Innovation Uncertainty, Day 30: Losing Our Way on Geographical Indications, Day 31: Canadian Trademark Law Overhaul, Day 32: Illusory Safeguards Against Encryption Backdoors, Day 33: Setting the Rules for a Future Pharmacare Program, Day 34: PMO Was… [read post]
7 Mar 2016, 1:55 am
. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences.Never too late 83 [week ending on Sunday 14 February] – Indigenous IP | Arnold J's latest judgment flags down the iconic London black cab | Life of a national/EU trade mark ... in a map | A comprehensive explanation of trademarks | Actavis v Lilly.Never… [read post]
4 Mar 2016, 7:21 am
The Trouble with the TPP has discussed how the agreement’s investor-state dispute settlement provisions do not meet the standard set by the Canadian government in CETA, do not address key concerns over policy making as illustrated by the Bilcon case, and raise enormous risks as demonstrated by the ongoing Eli Lilly dispute over Canadian patent law. [read post]
3 Mar 2016, 6:52 am
As compensation, Eli Lilly is seeking $500 million in damages. [read post]
3 Mar 2016, 6:37 am
It recently waded into the case that most clearly crystallizes the dangers of trade and IP in Canada: the Eli Lilly claim for compensation from Canadian taxpayers for hundreds of millions of dollars due to a pair of patent law decisions. [read post]
3 Mar 2016, 5:19 am
Last week’s “breaking news” post on West Virginia’s statutory restoration of the learned intermediary rule started us thinking about how every state now has pro-learned intermediary precedent. [read post]
1 Mar 2016, 10:06 am
Indianapolis, Indiana - An Indiana patent attorney for Plaintiff Eli Lilly & Company ("Lilly") of Indianapolis, Indiana filed a lawsuit in the Southern District of Indiana alleging that Biocon Limited of Bangalore, India will infringe its patented chemotherapy drug, which Lilly offers under the brand name ALIMTA. [read post]
1 Mar 2016, 7:34 am
Eli Lilly and Company et al, 2-15-cv-01202 (TXED February 26, 2016, Order) (Bryson, C.J.) [read post]
29 Feb 2016, 11:27 pm
. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences.Never too late 83 [week ending on Sunday 14 February] – Indigenous IP | Arnold J's latest judgment flags down the iconic London black cab | Life of a national/EU trade mark ... in a map | A comprehensive explanation of trademarks | Actavis v Lilly.Never… [read post]
26 Feb 2016, 1:21 pm
The patent cases where Justice Scalia authored the opinion for the Supreme Court are: Eli Lilly, Inc. v Medtronic, Inc., 496 U.S. 661 (1990), decided 7-2: the Supreme Court decided that 35 U.S.C. 271(e)(1) exempted from infringement the use of patented inventions reasonably related to the development and submission of information needed to obtain marketing approval of medical devices under the Federal Food, Drug and Cosmetic Act. [read post]
26 Feb 2016, 7:20 am
These SGLT2 drugs are currently approved for use by patients in the US: Invokana (canagliflozin) — Janssen Pharmaceuticals — FDA Approval: 2013 Invokamet (canagliflozin and metformin) — Janssen Pharmaceuticals — FDA Approval: 2014 Farxiga (dapagliflozin) — AstraZeneca Pharmaceuticals — FDA Approval: 2014 Xigduo XR (dapagliflozin and metformin extended-release) — AstraZeneca Pharmaceuticals — FDA Approval: 2014 Jardiance (empagliflozin) —… [read post]
23 Feb 2016, 1:53 am
Mrs Justice Rose is go go go in Lilly v Janssen stay applicationStays of proceedings are not easy in UK courts, as Janssen found out last week in Eli Lilly v Janssen Sciences [2016] EWHC 313, where Mrs Justice Rose refused to stay Lilly's revocation and declaration of non-infringement (DNI) action brought against Janssen's divisional patent - EP (UK) 2 305 282. [read post]
21 Feb 2016, 1:44 am
Are the undertakings offered by Janssen sufficient to reduce the commercial uncertainty faced by Eli Lilly to an acceptable level if a stay is granted? [read post]
